Less than a month after filing for bankruptcy, Insys Therapeutics gained a reprieve from some lawsuits as well as a path forward for regulatory approval of an opioid overdose treatment.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.
Facebook Inc. is taking steps to reduce promotion of products based on misleading health-related claims.
Century Therapeutics, a startup founded by Versant Ventures, launched with $250 million in hand and a focus on developing induced pluripotent stem cell-based therapies for the treatment of hematologic and solid malignancies.
Pfizer Inc. named former U.S. Food and Drug Administration Commissioner Scott Gottlieb to the company’s board of directors.
ImmunoGen shares fell after the company announced the slashing of 220 employees as part of an effort to reduce ongoing expenses while recovering from an FDA rejection of an ovarian cancer drug.
EVERSANA announced the appointment of Bhaskar Sambasivan to President, Patient Services and Chief Strategy Officer.
San Francisco is the first major city in the United States to ban the sale of e-cigarettes as officials look to control the rapid uptick in teenage use of nicotine devices made by companies such as Juul Labs Inc.
Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.
Akorn Inc. received a warning letter from the U.S. Food and Drug Administration regarding a manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker, sending the company’s shares down nearly 13 percent.